Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS).

"Declarations Conflict of interestDr. Hiroshi Nakase (HN) reports receiving personal fees from Abbvie Inc., Kissei Pharmaceutical Co., Ltd., KYORIN Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K, Takeda Pharmaceutical Co., Ltd., Pfizer Japan Inc., Celgene K.K., EA Pharma Co., Ltd., Zeria Pharmaceutical CO., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., D Daiichi Sankyo Co., Ltd., JIMRO Co., Ltd., as well as grants for commissioned/joint research from Hoya Group Pentax Medical, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company. Dr Yuki Hayashi (YH) and Dr. Daisuke Hirayama (DH) report no receipt of personal fees from any pharmaceutical companies. Dr. Takayuki Matsumoto (TM) reports receipt of personal fees from Abbvie Inc., Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K, Takeda Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and JIMRO Co., Ltd. Dr. Minoru Matsuura (MM) reports receipt of personal fees from AbbVie GK, Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co., Ltd., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co., Ltd., and Mochida Pharmaceutical Co., Ltd. Dr. Hideki Iijima (HI) report personal fees from AbbVie Inc, Janssen Pharmaceutical K.K., EA Pharma Co., Ltd., Eisai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Ltd., Mochida Pharmaceutical Co. Ltd., and research grants from AbbVie Inc., Nippon Kayaku Co., Ltd, Daiichi Sankyo Company, Ltd. Dr. Katsuyoshi Matsuoka (KM) reports personal fees from AbbVie Inc, Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Ltd., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd., Pfizer Lnc., EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., and commercial research funding from Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd, AbbVie GK, Nippon Kayaku Co., Ltd., EA pharma Co., Ltd. Dr. Naoki Ohmiya (NO) reports receiving grants for commissioned/joint research from Nippon Kayaku Co., Ltd. EA Pharma Co., Ltd., EA Pharma Co., Ltd. Dr. Shunji Ishihara (SI) reports receipt of personal fees from Takeda Pharmaceutical Co. Ltd and receiving grants for commissioned/joint research from Takeda Pharmaceutical Co. Ltd, Nippon Kayaku Co., Ltd., Astellas Pharma Inc., EA Pharma Co., Ltd., Zeria Pharmaceutical CO., Ltd., Daiichi Sankyo Company, Ltd., and JIMRO Co., Ltd. Dr. Fumihito Hirai (FH) reports receipt of personal fees from AbbVie GK, EA pharma Co., Ltd., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co. Ltd. Dr. Daiki Abukawa reports no receipt of personal fees from any pharmaceutical companies. Dr. Tadakazu Hisamatsu (TH) receipt of personal fees from EA pharma Co. Ltd., AbbVie GK, Celgene K.K., Janssen Pharmaceutical K.K., Pfizer Inc., Mitsubishi Tanabe Pharma Corporation, Kyorin Pharmaceutical Co. Ltd., JIMRO Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nichi-lko Pharmaceutical Co., Ltd., and commercial research funding from EA pharma Co., Ltd., AbbVie GK, Daiichi-Sankyo Co., Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Mochida Pharmaceutical Co., Ltd, Nippon Kayaku Co., Ltd., Kyorin Pharmaceutical Co., Ltd., JIMRO Co.,Ltd., Mochida Pharmaceutical Co., Ltd., and ZERIA Pharmaceutical Co., Ltd. Conflict of interest Dr. Hiroshi Nakase (HN) reports receiving personal fees from Abbvie Inc., Kissei Pharmaceutical Co., Ltd., KYORIN Pharmaceutical Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K, Takeda Pharmaceutical Co., Ltd., Pfizer Japan Inc., Celgene K.K., EA Pharma Co., Ltd., Zeria Pharmaceutical CO., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., D Daiichi Sankyo Co., Ltd., JIMRO Co., Ltd., as well as grants for commissioned/joint research from Hoya Group Pentax Medical, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company. Dr Yuki Hayashi (YH) and Dr. Daisuke Hirayama (DH) report no receipt of personal fees from any pharmaceutical companies. Dr. Takayuki Matsumoto (TM) reports receipt of personal fees from Abbvie Inc., Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K, Takeda Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and JIMRO Co., Ltd. Dr. Minoru Matsuura (MM) reports receipt of personal fees from AbbVie GK, Mitsubishi Tanabe Pharma Corporation, Nippon Kayaku Co., Ltd., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co., Ltd., and Mochida Pharmaceutical Co., Ltd. Dr. Hideki Iijima (HI) report personal fees from AbbVie Inc, Janssen Pharmaceutical K.K., EA Pharma Co., Ltd., Eisai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Ltd., Mochida Pharmaceutical Co. Ltd., and research grants from AbbVie Inc., Nippon Kayaku Co., Ltd, Daiichi Sankyo Company, Ltd. Dr. Katsuyoshi Matsuoka (KM) reports personal fees from AbbVie Inc, Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Ltd., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd., Pfizer Lnc., EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., and commercial research funding from Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd, AbbVie GK, Nippon Kayaku Co., Ltd., EA pharma Co., Ltd. Dr. Naoki Ohmiya (NO) reports receiving grants for commissioned/joint research from Nippon Kayaku Co., Ltd. EA Pharma Co., Ltd., EA Pharma Co., Ltd. Dr. Shunji Ishihara (SI) reports receipt of personal fees from Takeda Pharmaceutical Co. Ltd and receiving grants for commissioned/joint research from Takeda Pharmaceutical Co. Ltd, Nippon Kayaku Co., Ltd., Astellas Pharma Inc., EA Pharma Co., Ltd., Zeria Pharmaceutical CO., Ltd., Daiichi Sankyo Company, Ltd., and JIMRO Co., Ltd. Dr. Fumihito Hirai (FH) reports receipt of personal fees from AbbVie GK, EA pharma Co., Ltd., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co. Ltd. Dr. Daiki Abukawa reports no receipt of personal fees from any pharmaceutical companies. Dr. Tadakazu Hisamatsu (TH) receipt of personal fees from EA pharma Co. Ltd., AbbVie GK, Celgene K.K., Janssen Pharmaceutical K.K., Pfizer Inc., Mitsubishi Tanabe Pharma Corporation, Kyorin Pharmaceutical Co. Ltd., JIMRO Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nichi-lko Pharmaceutical Co., Ltd., and commercial research funding from EA pharma Co., Ltd., AbbVie GK, Daiichi-Sankyo Co., Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Mochida Pharmaceutical Co., Ltd, Nippon Kayaku Co., Ltd., Kyorin Pharmaceutical Co., Ltd., JIMRO Co.,Ltd., Mochida Pharmaceutical Co., Ltd., and ZERIA Pharmaceutical Co., Ltd."

"Funding This work was supported by Health and Labour Sciences Research Grants for research on intractable diseases from the Ministry of Health, Labour and Welfare of Japan. (Investigation and Research for intractable Inflammatory Bowel Disease)."

"This is a multicenter, registry cohort study conducted by the research study group on intractable inflammatory bowel disorder of the Ministry of Health, Labor and Welfare in Japan. The study has been conducted using information obtained from eligible patients. No new intervention was implemented for this study. The protocol of this study was approved by the IRB at each institution and registered publicly on the University Hospital Medical Information Network registration number UMIN000040656."